Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks

ASX energy share remains cheap despite strong outlook

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks

Moated AI-proof tech play hiding in the ASX 100

ChatGPT and large language models should be a tailwind for this company.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.4019.00-0.21%
CAC 408,157.8269.50-0.84%
DAX 4024,128.9826.47-0.11%
Dow JONES (US)49,230.7179.61-0.16%
FTSE 10010,379.0877.93-0.75%
HKSE25,978.0762.870.24%
NASDAQ24,836.60398.101.63%
Nikkei 22559,716.18575.950.97%
NZX 50 Index12,874.949.99-0.08%
S&P 5007,165.0856.680.80%
S&P/ASX 2008,786.5012.10-0.14%
SSE Composite Index4,079.9013.35-0.33%

Market Movers